试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-25
BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations
编号:NCT06032936登记状态:提前终止企业 / 申办者:LianBio LLC
药物 / 成分:BBP-398、osimertinib
登记的停止原因(原文):Business reason
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-24
Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
编号:NCT02013141登记状态:提前终止企业 / 申办者:Cumberland Pharmaceuticals
药物 / 成分:Telavancin
登记的停止原因(原文):FDA waived the pediatric study requirement for this application
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-24
Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis
编号:NCT02694393登记状态:提前终止企业 / 申办者:Schmidhofer, Mark, MD
药物 / 成分:sodium nitrite
登记的停止原因(原文):Protocol closed due to difficulty recruiting subjects and then expiration of investigational product and lack of a manufacturer.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-24
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
编号:NCT03250299登记状态:提前终止企业 / 申办者:Basilea Pharmaceutica
药物 / 成分:Microtubule-Targeted Agent BAL101553、Radiation Therapy
登记的停止原因(原文):Due to the National Cancer Institute's (NCI)-mandated termination of the Adult Brain Tumor Consortium which was conducting the study
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-24
Phase I/II Study of Avelumab in Pediatric Cancer Participants
编号:NCT03451825登记状态:提前终止企业 / 申办者:EMD Serono Research & Development Institute, Inc.
药物 / 成分:Avelumab、Avelumab
登记的停止原因(原文):Based on the limited activity observed with avelumab monotherapy in the pediatric population, the Phase II study part was cancelled.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-24
IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)
编号:NCT04524949登记状态:提前终止企业 / 申办者:Imcyse SA
药物 / 成分:IMCY-0098 450 μg、IMCY-0098 1350 μg、Placebo
登记的停止原因(原文):No efficacy at primary analysis after 1 year. Long term follow-up stopped
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-24
Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study
编号:NCT04536532登记状态:提前终止企业 / 申办者:Sunshine Lake Pharma Co., Ltd.
药物 / 成分:HEC121120 tablets、HEC121120 placebo tablets、entecavir tablets、entecavir placebo tablets
登记的停止原因(原文):Company decision to discontinue trial
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-24
Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy
编号:NCT04594070登记状态:提前终止企业 / 申办者:The University of Texas Medical Branch, Galveston
药物 / 成分:Ferrous sulfate
登记的停止原因(原文):Unable to recruit enough participants
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-24
Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS
编号:NCT04643691登记状态:提前终止企业 / 申办者:Assistance Publique Hopitaux De Marseille
药物 / 成分:Losartan 50 mg and Spironolactone 25 mg pillules oral use
登记的停止原因(原文):due to an Urgent Security Measure
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-06-21
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
编号:NCT03689244登记状态:提前终止企业 / 申办者:Actelion
药物 / 成分:Selexipag、Placebo
登记的停止原因(原文):The study did not demonstrate efficacy on the primary endpoint, PVR vs. placebo at wk 20 at a planned interim analysis.
查看官方原始记录 ↗